Oaktree Acquisition Corp. III Life Sciences (the “Company”), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities, priced its initial public offering of 17,500,000 units at a price of $10.00 per unit. Oaktree Acquisition Corp. III Life Sciences is the third public acquisition vehicle sponsored by an affiliate of Oaktree Capital Management, L.P. (“Oaktree”) and follows the successfully completed mergers between Oaktree Acquisition Corp. and Hims & Hers (a direct-to-consumer healthcare business) and between Oaktree Acquisition Corp. II and Alvotech (a global biosimilars business).
Read the full article: Oaktree Acquisition Corp. III Life Sciences Announces Pricing of $175M IPO //
Source: https://www.businesswire.com/news/home/20241023616170/en/Oaktree-Acquisition-Corp.-III-Life-Sciences-Announces-Pricing-of-175-Million-Initial-Public-Offering